An Insider Bought 40,408 Shares Of NRx Pharmaceuticals Inc. (NRXP)


As of Wednesday close, NRx Pharmaceuticals Inc.’s (NASDAQ:NRXP) stock was up $0.02, moving up 1.87 percent to $1.09. The average number of shares traded per day over the past five days has been 666,960 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0400 gain in that time frame. In the last twenty days, the average volume was 399,005, while in the previous 50 days, it was 279,888.

Since last month, NRXP stock rose 38.84%. Shares of the company fell to $0.7400 on 10/24/22, the lowest level in the past month. A 52-week high of $10.39 was reached on 01/06/22 after having rallying from a 52-week low of $0.49. Since the beginning of this year, NRXP’s stock price has dropped by -77.20% or -$3.6900, and marked a new high 3 times. However, the stock has declined by -89.51% since its 52-week high.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


NRXP stock investors should be aware that NRx Pharmaceuticals Inc. (NRXP) stock had its last reported insider trading activity 6 days ago on Nov 18. Hurvitz Chaim, the Director of the company, purchased of 40,408 shares for $1.10 on Nov 18. It resulted in a $44,449 investment by the insider. Hurvitz Chaim added 171,780 shares at an average price of $1.08 on Nov 17. The insider now owns 459,592 shares following the transaction. On Nov 17, 10% Owner Javitt Daniel C. sold 33,018 shares at $1.05 apiece. The transaction was valued at $34,745.

Financial Health

In the three months ended September 29, NRx Pharmaceuticals Inc.’s quick ratio stood at 4.60, while its current ratio was 4.60, showing that the company is able to pay off its debt. Based on annual data, NRXP earned $18000.0 in gross profit and brought in $115.8 million in revenue.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected NRx Pharmaceuticals Inc. to report -$0.14 quarterly earnings, the actual figure was -$0.14 per share. During the quarter, the company generated -$9.14 million in EBITDA. The liabilities of NRx Pharmaceuticals Inc. were 8.04 million at the end of its most recent quarter ended September 29. The value of shareholders’ equity is $67.64 million.

Technical Picture

This quick technical analysis looks at NRx Pharmaceuticals Inc.’s (NRXP) price momentum. With a historical volatility rate of 152.67%, the RSI 9-day stood at 60.05% on 23 November.

With respect to its five-day moving average, the current NRx Pharmaceuticals Inc. price is up by +3.81% percent or $0.0400. At present, NRXP shares trade +39.74% above its 20-day simple moving average and +98.11% percent above its 100-day simple moving average. However, the stock is currently trading approximately +36.25% above its SMA50 and -58.40% below its SMA200.

Stochastic coefficient K was 46.05% and Stochastic coefficient D was 52.09%, while ATR was 0.1258. Given the Stochastic reading of 52.68% for the 14-day period, the RSI (14) reading has been calculated as 60.65%.

Analyst Ratings

NRx Pharmaceuticals Inc. (NRXP) has been rated Buy by analysts. According to 0 brokerage firms, NRXP is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate NRx Pharmaceuticals Inc. stock as buy, with 2 recommending it as overweight.

With a median target price of $3.25, the current consensus forecast for the stock is $2.00 – $4.50. Based on these forecasts, analysts predict NRx Pharmaceuticals Inc. (NRXP) will achieve an average price target of $3.25.


Please enter your comment!
Please enter your name here